CJM-112
CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A) . CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways[1].
Product Specifications
UNSPSC
12352203
Target
Interleukin Related
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
[CJM-112]
References & Citations
[1]Maarouf M, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug;29 (5) :441-449.|[2]Maarouf M, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug;29 (5) :441-449.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
IL-17
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
252664-AP 100 µL
TIMM8B (Translocase of inner Mitochondrial Membrane 8 Homolog B (yeast), DDP2, FLJ21744, MGC102866, MGC117373, TIM8B) (AP) discontinued
Ask
View Details 
GTR15238564 1 Vial
Lentiviral mouse Procr shRNA (UAS) - Lentiviral mouse Procr shRNA (UAS, iRFP) plasmid
Ask
View Details